Authors: Joehar Hamdan, Ashley Truhlar, Earl H. Rudolph, Mahmoud Mahafzah.
Autoimmune hemolytic anemia (AIHA) presenting concomitantly with multiple myeloma (MM) has been reported in a limited number of cases. Here we report a case of MM initially presenting as AIHA that was subsequently treated with bortezomib (Velcade®, formerly PS-341). Initial treatment of AIHA became refractory to corticosteroids, however subsequent diagnosis and treatment of MM with bortezomib yielded significant clinical responses to both the MM and the relapsed AIHA. Bortezomib is currently approved for treatment of MM and mantle cell lymphoma, but may have potential to treat other hematologic and malignant disorders.
View/Download pdf